

ETHICS ADVISORY BOARD

Illumina is committed to building our company with integrity and ethical business behavior.

What is Illumina's Ethics Advisory Board?

Since 2008, Illumina convened an Ethics Advisory Board (EAB) to ensure that Illumina acts ethically and justly in its business operations. The EAB meets quarterly to advise and provide recommendations regarding ethical issues involving Illumina's existing, emerging, and prospective products, services, and processes both from a research and clinical perspective. This includes providing strategic advice to Illumina regarding emerging ethical issues, policies, and regulations relevant to the genomics industry.



Clement Adebamowo, BM, ChB, ScD, FWACS, FACS

Clement Adebamowo is Professor of Epidemiology, Associate Director of Population Science and Director for Global Health Cancer Research at the Greenebaum Comprehensive Cancer Center, and member of the Institute of Human Virology at the University of Maryland School of Medicine. He was foundation chair of the Nigerian National Health Research Ethics Committee, Principal Investigator of several NIH-funded genomics, cancer and bioethics research and training projects including the Indigene Study, a project for improvement of comprehension of informed consent for genomic ethics in African communities that incorporates an online database of words related to genomics in local African languages.



Freda Lewis-Hall, MD, DFAPA, MFPM

During her 35-year career in medicine, Dr. Freda Lewis-Hall has been on the frontlines of health care as a clinician, educator, researcher, and leader in the biopharmaceuticals and life sciences industries. Freda most recently served as Pfizer, Inc.'s Chief Medical Officer and Executive Vice President until the end of 2018 and as Chief Patient Officer and Executive Vice President during 2019. In these roles, Freda expanded outreach to patients, reshaped the focus on patient engagement and inclusion, improved health information and education, and amplified the voice of the patient within company culture and decision-making.



Leslie Biesecker, M.D.

Les is a clinical and molecular geneticist and is the chief of the Medical Genomics and Metabolic Genetics Branch at the National Human Genome Research Institute (NHGRI) of the National Institutes of Health. Dr. Biesecker directs the ClinSeq project with goals to improve medical care for patients and provide generalized knowledge about genetic disease. He is a member of the National Academy of Medicine.



Nita Farahany, J.D., Ph.D.

Nita is the Robinson O. Everett Professor of Law & Philosophy at Duke University, and the Director of Duke Science & Society Initiative. President Obama appointed Nita to the Presidential Commission for the Study of Bioethical Issues in 2010 and she served until 2017. She is a leading scholar on the ethical, legal, and social implications of biosciences and emerging technologies, particularly those related to neuroscience and behavioral genetics.



Glenn Cohen, J.D.

Glenn is a Deputy Dean and Professor of Law at Harvard Law School and the Faculty Director for the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics. An award-winning academic and lawyer, Glenn's work has appeared in leading publications and his amicus briefs have been discussed by the United States Supreme Court. His current research focuses on big data, health information technologies, research ethics, reproductive technology, and health policy.



Charmaine Royal, Ph.D.

Charmaine is an Associate Professor of African & African American Studies, Biology, Global Health, and Family Medicine & Community at Duke University. She directs the Center on Genomics, Race, Identity, and Difference and the Center for Truth, Racial Healing, and Transformation at the Social Science Research Institute. Charmaine's main academic interest is in addressing root causes and implementing sustainable solutions regarding problems of race and racism in research, healthcare, and society.